Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Подозрение на глаукому

Список литературы

  1. Национальное руководство по глаукоме для практикующих врачей. Изд. 4-е, испр. и доп. / Под ред. Е.А. Егорова, В.П. Еричева. М.: ГЭОТАР-Медиа, 2019: 384.
  2. European Glaucoma Society Terminology and Guidelines for Glaucoma (4th Edition). Savona: PubliComm, 2014: 196.
  3. Basic and Clinical Science Course. Section 10. Glaucoma / Ed. C.A. Girkin. San Francisco: AAO, 2018: 262.
  4. Primary Open-Angle Glaucoma Suspect. Prefered Practice Pattern / Ed. S. Garratt. San Francisco: AAO, 2016; 76.
  5. Prum B.E., Lim M.C., Mansberger S.L. et al. Primary open-angle glaucoma suspect preferred practice pattern® guidelines. Ophthalmology. 2016; 123(1): 112-151.
  6. Chang R.T., Singh K. Glaucoma Suspect: Diagnosis and Management. Asia Pac J Ophthalmol (Phila). 2016; 5(1): 32-37.
  7. Glaucoma: Diagnosis and Management of Chronic Open-Angle Glaucoma and Ocular Hypertension. Methods, evidence and guidance / Ed. J. Sparrow. London: NICE, 2009: 280.
  8. Leske M.C., Connell A.M., Schachat A.P., Hyman L. The Barbados Eye Study: prevalence of open-angle glaucoma. Arch Ophthalmol. 1994; 112(6): 821-829.
  9. Mitchell P., Smith W., Attebo K., Healey P.R. Prevalence of open-angle glaucoma in Australia: the Blue Mountains Eye Study. Ophthalmology. 1996; 103(10): 1661-1669.
  10. Vajaranant T.S., Wu S., Torres M., Varma R. The changing face of primary open-angle glaucoma in the United States: demographic and geographic changes from 2011 to 2050. Am J Ophthalmol. 2012; 154(2): 303-314.
  11. Klein B.E., Klein R. Projected prevalences of age-related eye diseases. Invest Ophthalmol Vis Sci. 2013; 54(1): 14-17.
  12. Rossetti L., Digiuni M., Giovanni M., et al. Blindness and Glaucoma: A Multicenter Data Review from 7 Academic Eye Clinics. PLoS ONE. 2015; 10(8): e0136632.
  13. Fujino Y., Asaoka R., Murata H. et al. Evaluation of Glaucoma Progression in Large- Scale Clinical Data: The Japanese Archive of Multicentral Databases in Glaucoma (JAMDIG). Invest Ophthalmol Vis Sci. 2016; 57(4): 2012-2020.
  14. Liu B., McNally S., Kilpatrick J.I. et al. Aging and ocular tissue stiffness in glaucoma. Surv Ophthalmol. 2018; 63(1): 56-74.
  15. Sommer A., Tielsch J.M., Katz J. et al. Racial differences in the cause-specific prevalence of blindness in East Baltimore. N Engl J Med. 1991; 325(20): 1412-1417.
  16. Stein J.D., Kim D.S., Niziol L.M. et al. Differences in rates of glaucoma among Asian Americans and other racial groups, and among various Asian ethnic groups. Ophthalmology. 2011; 118(6): 1031-1037.
  17. Rudnicka A.R., Mt-Isa S., Owen C.G. et al. Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis. Invest Ophthalmol Vis Sci. 2006; 47(10): 4254-4261.
  18. Leske M.C., Wu S.Y., Honkanen R. et al. for the Barbados Eye Studies Group. Nine- year incidence of open-angle glaucoma in the Barbados Eye Studies. Ophthalmology 2007; 114(6): 1058-1064.
  19. Mukesh B.N., McCarty C.A., Rait J.L., Taylor H.R. Five-year incidence of open-angle glaucoma: the visual impairment project. Ophthalmology. 2002; 109(6): 1047-1051.
  20. Vajaranant T.S., Pasquale L.R. Estrogen deficiency accelerates aging of the optic nerve. Menopause. 2012; 19(8): 942-947.
  21. Quigley H.A., Broman A.T. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006; 90(3): 262-267.
  22. Tham Y.C., Li X., Wong T.Y. et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014; 121(11): 2081-2090.
  23. Wolfs R.C., Klaver C.C., Ramrattan R.S. et al. Genetic risk of primary open-angle glaucoma. Population-based familial aggregation study. Arch Ophthalmol. 1998; 116(12): 1640-1645.
  24. Leske M.C., Nemesure B., He Q. et al. Patterns of open-angle glaucoma in the Barbados Family Study. Ophthalmology. 2001; 108(6): 1015-1022.
  25. Abu-Amero K., Kondkar A.A., Chalam K.V. An Updated Review on the Genetics of Primary Open Angle Glaucoma. Int. J. Mol. Sci. 2015; 16(12): 28886-28911.
  26. Asefa N.G., Snieder H. Heritability of glaucoma and glaucoma-related endophenotypes: systematic review and meta-analysis protocol. BMJ Open. 2018; 8(2): e019049.
  27. Kong X., Chen Y., Chen X., Sun X. Influence of family history as a risk factor on primary angle closure and primary open angle glaucoma in a Chinese population. Ophthalmic Epidemiol. 2011; 18(5): 226-232.
  28. Gordon M.O., Kass M.A. The Ocular Hypertension Treatment Study. Design and Baseline Description of the Participants. Arch Ophthalmol. 1999; 117(5): 573-583.
  29. Johnson C.A., Celtner J.L., Cello K.E. et al. Baseline visual field characteristics in the ocular hypertension treatment studyHistorical image. Ophthalmology. 2002; 109(3): 432-437.
  30. Kass M.A., Heuer D.K., Higginbotham E.J. et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypertensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 2002; 120(6): 701-713.
  31. Gordon M.O., Beiser J.A., Brandt J.D. et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120(6): 714-720.
  32. Водовозов А.М. Толерантное и интолерантное внутриглазное давление при глаукоме. Волгоград: БИ, 1991: 160.
  33. Le A., Mukesh B.N., McCarty C.A., Taylor H.R. Risk factors associated with the incidence of open-angle glaucoma: the visual impairment project. Invest Ophthalmol Vis Sci. 2003; 44(9): 3783-3789.
  34. Weinreb R.N., Friedman D.S., Fechtner R.D. et al. Risk assessment in the management of patients with ocular hypertension. Am J Ophthalmol. 2004; 138(3): 458-467.
  35. Czudowska M.A., Ramdas W.D., Wolfs R.C. et al. Incidence of glaucomatous visual field loss: a ten-year follow-up from the Rotterdam Study. Ophthalmology. 2010; 117(9): 1705-1712.
  36. Chauhan B.C., Mikelberg F.S. Artes P.H. et al. Canadian Glaucoma Study. Impact of Risk Factors and Intraocular Pressure Reduction on the Rates of Visual Field Change. Arch Ophthalmol. 2010; 128(10): 1249-1255.
  37. Drance S., Anderson D.R., Schulzer M. for the Collaborative Normal-Tension Glaucoma Study Group. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. Am J Ophthalmol 2001; 131(6): 699-708.
  38. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS), 7: the relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130(4): 429-440.
  39. Musch D.C., Gillespie B.W., Lichter P.R. et al. аnd the CIGTS Study Investigators. Visual field progression in the Collaborative Initial Glaucoma Treatment Study the impact of treatment and other baseline factors. Ophthalmology 2009; 116(2): 200-207.
  40. Leske M.C., Heijl A., Hyman L. et al. for the EMGT Group. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology 2007; 114(11): 1965- 1972.
  41. Scheetz T.E., Faga B., Ortega L. et al. Glaucoma Risk Alleles in the Ocular Hypertension Treatment Study (OHTS). Ophthalmology. 2016; 123(12): 2527-2536.
  42. Баранов В.И., БрежневА.Ю. Псевдоэксфолиативный синдром в Центральной России: клинико-эпидемиологическое исследование. Российский офтальмологический журнал. 2012; 5(1): 22-24.
  43. Ritch R. Exfoliation syndrome: the most common identifiable cause of open-angle glaucoma. J Glaucoma 1994; 3(2): 176-178.
  44. Puska P.M. Unilateral exfoliation syndrome: conversion to bilateral exfoliation and to glaucoma: a prospective 10-year follow-up study. J Glaucoma. 2002; 11(6): 517-524.
  45. Jeng S.M., Karger R.A., Hodge D.O. et al. The risk of glaucoma in pseudoexfoliation syndrome. J Glaucoma. 2007; 16(1): 117-121.
  46. Heijl A., Bengtsson B., Hyman L. et al. Natural history of open angle glaucoma. Ophthalmology. 2009; 116(12): 2271-2276.
  47. Siddiqui Y., Ten Hulzen R.D., Cameron J.D. et al. What is the risk of developing pigmentary glaucoma from pigment dispersion syndrome? Am J Ophthalmol. 2003; 135(6): 794-799.
  48. Niyadurupola N., Broadway D.C. Pigment dispersion syndrome and pigmentary glaucoma - a major review. Clin. Exp. Ophthalmol. 2008; 36(9): 868-882.
  49. Щуко А.Г., Юрьева Т.Н., Чекмарева Л.Т., Малышев В.В. Глаукома и патология радужки. М.: ООО “Компания БОРГЕС”, 2009: 166.
  50. Lascaratos G., Shah A., Garway-Heath D.F. The Genetics of Pigment Dispersion Syndrome and Pigmentary Glaucoma. Surv Ophthalmol. 2013; 58(2): 164-175.
  51. Herndon L.W., Lee D.A., Netland P.A. Rethinking pachymetry and intraocular pressure. Rev Ophthalmol. 2002; 2(1): 88-90.
  52. Brandt J.D., Beiser J.A., Gordon M.O., Kass M.A. Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study. Am J Ophthalmol. 2004: 138(5): 717-722.
  53. Medeiros F.A., Weinreb R.N. Is corneal thickness an independent risk factor for glaucoma? Ophthalmology. 2012; 119(3): 435-436.
  54. Leske M.C., Wu S.Y., Hennis A. et al. Risk factors for incident open-angle glaucoma: the Barbados Eye Studies. Ophthalmology. 2008; 115(1): 85-93.
  55. Mitchell P., Hourihan F., Sandbach J., Wang J.J. The relationship between glaucoma and myopia: the Blue Mountains Eye Study. Ophthalmology. 1999; 106(10): 2010- 2015.
  56. Grodum K., Heijl A., Bengtsson B. Refractive error and glaucoma. Acta Ophthalmol Scand. 2001; 79(6): 560-566.
  57. Wong T.Y., Klein B.E., Klein R. et al. Refractive errors, intraocular pressure, and glaucoma in a white population. Ophthalmology. 2003; 110(1): 211-217.
  58. Xu L., Wang Y., Wang S., Jonas J.B. High myopia and glaucoma susceptibility the Beijing Eye Study. Ophthalmology. 2007; 114(2): 216-220.
  59. Perera S.A., Wong T.Y., Tay W.T. et al. Refractive error, axial dimensions, and primary open-angle glaucoma: the Singapore Malay Eye Study. Arch Ophthalmol. 2010; 128(7): 900-905.
  60. Qiu M., Wang S.Y., Singh K., Lin S.C. Association between myopia and glaucoma in the United States population. Invest Ophthalmol Vis Sci 2013; 54: 830-835.
  61. Tielsch J.M., Katz J., Sommer A. et al. Hypertension, perfusion pressure, and primary open-angle glaucoma. A population-based assessment. Arch Ophthalmol. 1995; 113(2): 216-221.
  62. Bonomi L., Marchini G., Marraffa M. et al. Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study. Ophthalmology. 2000; 107(7): 1287-1293.
  63. Hulsman C.A., Vingerling J.R., Hofman A. et al. Blood pressure, arterial stiffness, and open-angle glaucoma: the Rotterdam study. Arch Ophthalmol. 2007; 125(6): 805-812.
  64. Topouzis F., Wilson M.R., Harris A. et al. Association of open-angle glaucoma with perfusion pressure status in the Thessaloniki Eye Study. Am J Ophthalmol. 2013; 155(5): 843-51.
  65. Zhao D., Cho J., Kim M.H., Guallar E. The association of blood pressure and primary open-angle glaucoma: a meta-analysis. Am J Ophthalmol. 2014; 158(3): 615-627.
  66. Salles G.F., Reboldi G., Fagard R.H. et al. Prognostic Effect of the Nocturnal Blood Pressure Fall in Hypertensive Patients: The Ambulatory Blood Pressure Collaboration in Patients with Hypertension (ABC-H) Meta-Analysis. Hypertension. 2016; 67(4): 693-700.
  67. Bengtsson B., Leske M.C., Yang Z., Heijl A. Disc hemorrhages and treatment in the early manifest glaucoma trial. Ophthalmology. 2008; 115(11): 2044-2048.
  68. Nouri-Mahdavi K., Hoffman D., Coleman A.L. et al. Predictive Factors for Glaucomatous Visual Field Progression in the Advanced Glaucoma Intervention Study. Ophthalmology. 2004; 111(9): 1627-1635.
  69. Weinreb R.N. Khaw P.T. Primary open-angle glaucoma. Lancet. 2004; 363(9422): 1711-1720.
  70. Orzalesi N., Rossetti L., Omboni S. Vascular risk factors in glaucoma: the results of a national survey. Graefe’s Arch Clin Exp Ophthalmol. 2007; 245(6): 795-802.
  71. Chauhan B.C., Mikelberg F.S., Balaszi A.G. et al. Canadian Glaucoma Study. Risk Factors for the Progression of Open-angle Glaucoma. Arch Ophthalmol. 2008; 126(8): 1030-1036.
  72. Topouzis F., Coleman A.L., Harris A. et al. Factors associated with undiagnosed open-angle glaucoma: the Thessaloniki Eye Study. Am J Ophthalmol. 2008; 145(2): 327-335.
  73. Нестеров А.П. Глаукома. М.: Медицинское информационное агентство, 2008: 360.
  74. Волков В.В., Сухинина Л.Б., Устинова Е.И. Глаукома, преглаукома, офтальмогипертензия. Л.: Медицина, 1985: 216.
  75. Ерошевский Т.И., Бранчевская С.Я., Асланов В.С., Комплексная оценка параметров глазного дна в норме и при глаукоме. Вестник офтальмологии. 1979; 4: 3-5
  76. Ерошевский Т.И., Лукова Н.Б., Куданкина Т.Д., Пятаеа И.Г. О дифференциальной диагностике эссенциальной глазной гипертензии и начальной открытоугольной глаукомы. Вестник офтальмологии. 1983; 4: 3-5.
  77. Crick R.P. Epidemiology and Screening of Open-Angle Glaucoma. Curr Opin Ophthalmol. 1994; 5(2): 3-9.
  78. Алексеев В.Н., Егоров Е.А., Мартынова Е.Б. О распределении уровней внутриглазного давления в нормальной популяции. РМЖ Клиническая офтальмология. 2001; 2(2): 38-40.
  79. Егоров Е.А., Куроедов А.В. Отдельные клинико-эпидемиологические характеристики глаукомы в странах СНГ и Грузии. Результаты многоцентрового открытого ретроспективного исследования (часть 1). Клиническая офтальмология. 2011; 3: 97-100.
  80. Егоров Е.А., Куроедов А.В. Отдельные клинико-эпидемиологические характеристики глаукомы в странах СНГ и Грузии. Результаты многоцентрового открытого ретроспективного исследования (часть 2). Клиническая офтальмология. 2012; 1: 19-22.
  81. Нероев В.В., Киселева О.А., Бессмертный А.М. Основные результаты мультицентрового исследования эпидемиологических особенностей первичной открытоугольной глаукомы в Российской Федерации. Российский офтальмологический журнал. 2013; 6(3): 4-7.
  82. Авдеев Р.В., Александров А.С., Басинский А.С. и соавт. Клинико- эпидемиологическое исследование факторов риска развития и прогрессирования глаукомы. Российский офтальмологический журнал. 2013; 6(3): 9-16.
  83. Foster P.J., Buhrmann R., Quigley H.A., Johnson G.J. The definition and classification of glaucoma in prevalence surveys. Br J Ophthalmol. 2002; 86(2): 238-242.
  84. Varma R., Ying-Lai M., Francis B.A. et al. Los Angeles Latino Eye Study Group. Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study. Ophthalmology. 2004; 111(8): 1439-1448.
  85. Armaly M.F. The Des Moines population study of glaucoma. IOVS. 1966; 1(5): 618- 628.
  86. Удинцов Е.И. Успехи отечественной офтальмологии и профилактика глазных заболеваний. М.: Издательство “Наука”, 1966: 240.
  87. Kini M.M., Leibowitz H.M., Colton T. et al. Prevalence of Senile Cataract, Diabetic Retinopathy, Senile Macular Degeneration, and Open-Angle Glaucoma In The Framingham Eye Study. Am J Ophthalmol. 1978; 85(1): 28-34. https://doi.org/10.1016/s0002-9394(14)76661-9
  88. Chisholm I.A., Drance S.M., To T. The glaucoma suspect: differentiation of the future glaucoma eye from the non-glaucomatous suspect eye. Graefes Clin Exp Ophthalmol. 1989; 227: 110-113.
  89. Нестеров А.П., Черкасова И.Н., Басинский С.Н. Офтальмогипертензия: результаты десятилетнего динамического наблюдения. Вестник офтальмологии. 1990; 1: 3-5.
  90. Tielsch J.M., Katz J., Singh K. et al. A population-based evaluation of glaucoma screening: the Baltimore Eye Survey. Am J Epidemiol. 1991; 134: 1102-1110.
  91. Leske M.C., Connell A.M., Wu S.Y. et al. Risk factors for open-angle glaucoma: The Barbados eye Study. Arch Ophthalmol. 1995; 113: 918-924.
  92. Страхов В.В., Алексеев В.В. Динамическая ригидометрия. Вестник офтальмологии. 1995; 1: 18-20.
  93. Leske M.C., Connell A.M., Wu S.Y. et al. Distribution of intraocular pressure. The Barbados Eye Study. Arch Ophthalmol. 1997; 115(8): 1051-1507.
  94. Miglior S., Zeyen T., Pfeiffer N. et al. Results of the European Glaucoma Prevention Study. Ophthalmology. 2005;112(9):366-375.
  95. Behrouzi Z., Rabei H.M., Azizi F. et al. Prevalence of Open-angle Glaucoma, Glaucoma Suspect, and Ocular Hypertension in Thyroid-related Immune Orbitopathy. Glaucoma 2007; 16: 358-362.
  96. Егоров Е.А., Басинский С.Н. Клинические лекции по офтальмологии. М.: Издательская группа «ГЭОТАР-Медиа», 2007: 320.
  97. Khandekar R., Jaffer, M.A., Al-Raisi A. et al. Oman Eye Study 2005: Prevalence and Determinants of Glaucoma. J East Mediterr Health. 2008; 14(6): 1349-1359.
  98. Chihara E. Assessment of true intraocular pressure: the gap between theory and practical data. Surv Ophthalmol. 2008; 53(3): 203-218.
  99. Kornmann H.L., Giaconi J.A. Treatment Initiation in Glaucoma Suspects. US Ophthalmic Rev. 2014; 7(1): 45-49.
  100. Tuli D., Sihota R., Das R.C. et al. Glaucoma Suspect. Delhi J Ophthalmol. 2014; 24(3): 199-206.
  101. Saboo U.S., Amparo F., Shikari H., Dana R. Prevalence of Ocular Hypertension and Glaucoma in Patients with Chronic Ocular Graft-versus-host Disease. Graefes Arch Clin Exp Ophthalmol. 2016; 254(5): 923-928.
  102. Авдеев Р.В., Александров А.С., Бакунина Н.А. и др. Подозрение и начальная стадия глаукомы: дифференциально-диагностические критерии». Российский офтальмологический журнал. 2017; 4: 5-15.
  103. Al-Aswad L.A., Joiner D.B., Wang X. et al. Screening for glaucoma in populations at high risk: The eye screening New York project. Cogent Medicine. 2017: 4: 1367059
  104. Modjtahedi B.S., Chu K., Luong T.Q. et al. Two-year outcomes of a pilot glaucoma suspect telemedicine monitoring program. Clin Ophthalmol. 2018;12: 2095-2102.
  105. Еричев В.П., Панюшкина Л.А. Современный взгляд на офтальмогипертензию. Вестник офтальмологии. 2019; 5: 305-311.
  106. Devalla S.K., Liang Z., Pham T.H. et al. Glaucoma management in the era of artificial intelligence. Br J Ophthalmol 2019; 104(3): 301-311.
  107. Chamard C., Villain M., Bron A. et al. Prevalence of Unknown Ocular Hypertension, Glaucoma Suspects, and Glaucoma in Patients Seen in an Ophthalmology Center in France. Ophthalmic Res. 2020; 63(3): 295-301.
  108. Kelly S.R., Khawaja A.P., Bryan S.R. et al. Progression from ocular hypertension to visual field loss in the English hospital eye service. Br J Ophthalmol. 2020. doi: 10.1136/bjophthalmol-2019-315052.
  109. Phu J., Khuu S.K., Agar A. et al. Visualizing the Consistency of Clinical Characteristics that Distinguish Healthy Persons, Glaucoma Suspect Patients, and Manifest Glaucoma Patients. Ophthalmology. Glaucoma. 2020; 3: 274-287.
  110. Leibowitz H.M., Krueger D.E., Maunder L.R. et al. The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Surv Ophthalmol. 1980; 24(Suppl): 335-610.
  111. International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10). WHO Version for; 2016. URL: https://icd.who.int/browse10/2016/en#/H40-H42 (дата обращения 06.09.2020).
  112. Buck's 2019 ICD-10-CM Physician Edition E-Book, 1st Ed. New York: Saunders, 2019: 1600.
  113. Нестеров А.П., Бунин А.Я. О новой классификации первичной глаукомы. Вестник офтальмологии. 1977; 5; 38-42.
  114. Нестеров А.П., Егоров Е.А. Классификация глаукомы. Клиническая офтальмология. 2001; 2(2): 35-37.
  115. Malik R., Swanson W.H., Garway-Heath D.F. «Structure-function relationship» in glaucoma: past thinking and current concepts. Clin Exp Ophthalmol. 2012; 40: 369- 380.
  116. Bierings R.A.J.M., van Sonderen F.L.P. Jansonius N.M. Visual complaints of patients with glaucoma and controls under optimal and extreme luminance conditions. Acta Ophthalmol. 2018; 96(3): 288-294.
  117. Enoch J., Jones L., Taylor D.J. et al. How do different lighting conditions affect the vision and quality of life of people with glaucoma? A systematic review. Eye. 2020; 34(1): 138-154.
  118. Peters D., Bengtsson B., Heijl A. Factors associated with lifetime risk of open-angle glaucoma blindness. Acta Ophthalmologica. 2014; 92(5): 421-425.
  119. Friedman D.S., Wilson M.R., Liebmann J.M. et al. An evidence-based assessment of risk factors for the progression of ocular hypertension and glaucoma. Am J Ophthalmol. 2004; 138(3): 19-31.
  120. Coleman AL, Miglior S. Risk factors for glaucoma onset and progression. Surv Ophthalmol. 2008; 53(1):3-10.
  121. Intraocular Pressure. Consensus Series - 4. / Ed. R.N. Weinreb, J.D. Brandt, D. Garway-Heath, F. Medeiros. Amsterdam: Kugler Publications, 2007: 128.
  122. Diagnosis of Primary Open Angle Glaucoma. Consensus Series - 10 / Ed. R.N. Weinreb., D. Garway-Heath, C. Leung, F. Medeiros, J. Liebmann. Amsterdam: Kugler Publications, 2017: 234.
  123. Quigley H.A., Katz.J., Derick.R.J.et al. An evaluation of optic disc and nerve fiber layer examinations in monitoring progression of early glaucoma damage. Ophthalmology 1992; 99:19-28.
  124. Quigley H.A., Addicks E.M., Green W.R. Optic nerve damage in human glaucoma. III. Quantitative correlation of nerve fiber loss and visual field defects in glaucoma, ischemic neuropathy, papilledema and toxic neuropathy. Arch Ophthalmol. 1982; 100: 135-146.
  125. Quigley H.A., Dunkelberger G.R., Green W.R. Retinal ganglion cell atrophy correlated with automated perimetry in human eyes with glaucomа. Am J Ophthalmol. 1989; 107(5): 453-464.
  126. Anton A., Zangwill L., Emdadi A. et al. Nerve fiber layer measurements with scanning laser polarimetry in ocular hypertension. Arch Ophthalmol. 1997; 115: 331-334.
  127. Егоров Е.А., Нестеров А.П. Первичная открытоугольная глаукома / в кн. Офтальмология. Национальное руководство под. ред. С.Э. Аветисова, Е.А. Егорова, Л.К. Мошетовой, Х.П. Тахчиди. М.: ГЭОТАР-Медиа, 2018: 713-726.
  128. Cook J.A., Botello A.P., Elders A. et al. Systematic review of the agreement of tonometers with Goldmann applanation tonometry. Ophthalmology. 2012; 119(8): 1552-1557.
  129. Sagri D., Lösche C.C., Bestges B.B., Krummenauer F. Is There Really Agreement between Rebound and Goldmann Applanation Tonometry Methods? Results of a Systematic Review of the Period 01/2005 to 08/2014. Klin Monbl Augenheilkd. 2015; 232(7): 850-857.
  130. Балашевич Л.И., Качанов А.Б., Никулин С.А. и др. Влияние толщины роговицы на пневмотонометрические показатели внутриглазного давления. Офтальмохирургия. 2005; 1: 31-33.
  131. Алексеев В.Н., Егоров Е.А., Мартынова Е.Б. О распределении уровней внутриглазного давления в нормальной популяции. РМЖ. Клиническая офтальмология. 2001; 2(2): 38-40.
  132. Егоров Е.А., Еричев В.П., Куроедов А.В. и др. Показатели офтальмотонометрии в здоровой популяции. Национальный журнал глаукома. 2018; 17(2): 91-98.
  133. Colton D., Ederer F. The Distribution of Intraocular Pressure in the General Population. Surv Ophthalmol. 1980; 25(3): 123-129.
  134. Егоров Е.А., Петров С.Ю., Городничий В.В. и др. Тонометрическое внутриглазное давление у взрослого населения: популяционное исследование. Национальный журнал глаукома. 2020; 19(2): 39-50.
  135. Ittoop S.M., SooHoo J.R., Seibold L.K. et al. Systematic Review of Current Devices for 24-h Intraocular Pressure Monitoring. Adv Ther. 2016; 33(10): 1679-1690.
  136. Konstas A.G., Kahook M.Y., Araie M. et al. Diurnal and 24-h Intraocular Pressures in Glaucoma: Monitoring Strategies and Impact on Prognosis and Treatment. Adv Ther. 2018. 35(11): 1775-1804.
  137. Краснов М.М. Клиностатическая проба для ранней диагностики глаукомы. Вестник офтальмологии. 1963; 1: 26-28.
  138. Хадикова Э.В. Ортостатические колебания уровня внутриглазного давления в норме и при глаукоме. Вестник ОГУ. 2004; 12: 45-46.
  139. Prata T.S., De Moraes C.G., Kanadani F.N. Posture-induced intraocular pressure changes: considerations regarding body position in glaucoma patients. Surv Ophthalmol. 2010; 55(5): 445-453.
  140. Нестеров А.П., Егоров Е.А. Клинические особенности глаукоматозной атрофии зрительного нерва. Вестник офтальмологии. 1978; 1: 5-8.
  141. Saccà S.C., Rolando M., Marletta A. et al. Fluctuations of intraocular pressure during the day in open-angle glaucoma, normal-tension glaucoma and normal subjects. Ophthalmologica. 1998; 212(2): 115-119.
  142. Bengtsson B., Leske M.C., Hyman L., Heijl A. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology. 2007; 114(2): 205-209.
  143. Астахов Ю.С., Устинова Е.И., Катинас Г.С. и др. О традиционных и современных способах исследования колебаний офтальмотонуса. Офтальмологические ведомости. 2008; 1(2): 7-12.
  144. Leske M.C., Heijl A., Hussein M., Bengtsson B., Hyman L., Komaroff E. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003; 121(1): 48-56.
  145. Stewart W.C., Konstas A.G.P., Nelson L.A., Kruft B. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology. 2008; 115(7): 1117-1122.
  146. Абышева Л.Д., Авдеев Р.В., Александров А.С. и др. Оптимальные характеристики верхней границы офтальмотонуса у пациентов с развитой стадией первичной открытоугольной глаукомы с точки зрения доказательной медицины. Клиническая офтальмология. 2015; 3: 111-123
  147. Diaconita V., Quinn M., Jamal D. et al. Washout Duration of Prostaglandin Analogues: A Systematic Review and Meta-analysis. J Ophthalmol. 2018; 2018: 3190684.
  148. Congdon N.G., Spaeth G.L., Augsburger J. et al. A proposed simple method for measurement in the anterior chamber angle: biometric gonioscopy. Ophthalmology. 1999; 106(11): 2161-2167.
  149. Шульпина Н.Б. Биомикроскопия глаза. М.: Медицина. 1974: 264.
  150. Spaeth G.L. The normal development of the human anterior chamber angle: a new system of descriptive grading. Trans. Ophthalmol. Soc. UK. 1971;91:709-739.
  151. Gonioscopy anatomy of the angle of the anterior chamber of the eye. In. SRe, ed. In: Shaffer R.N. Stereoscopic manual of gonioscopy. St. Louis, Mosby, 1962: 92.
  152. Sakata L.M., Lavanya R., Friedman D.S. et al. Comparison of gonioscopy and anterior segment ocular coherence tomography in detecting angle closure in different quadrants of the anterior chamber angle. Ophthalmology. 2008; 115(5): 769-774.
  153. Jonas J.B., Gusek G.C., Naumann G.O.H. Optic disc, cup and neuroretinal rim size, configuration and correlations in normal eyes. Invest Ophthalmol Vis Sci. 1998; 29(7): 1151-1158.
  154. Morgan J.E., Bourtsoukli I., Rajkumar K.N. et al. The accuracy of the inferior.superior.nasal.temporal neuroretinal rim area rule for diagnosing glaucomatous optic disc damage. Ophthalmology. 2012; 119(4): 723-730.
  155. Harizman N., Oliveira C., Chiang A. et al. The ISNT rule and differentiation of normal from glaucomatous eyes. Arch Ophthalmol. 2006; 124: 1579-1583.
  156. Куроедов А.В., Городничий В.В., Огородникова В.Ю. и др. Офтальмоскопическая характеристика изменений диска зрительного нерва и слоя нервных волокон при глаукоме (пособие для врачей). М.: «Дом печати «Столичный бизнес», 2011: 48.
  157. Егоров Е.А. Фото- и стереофотографические методики изучения глазного дна. Военно-медицинский журнал. 1977; 5: 46-47.
  158. Glaucoma Imaging / Eds. Iester M., Garway-Heath D., Lemij H. Savona: PubliComm, 2017: 144.
  159. Spaeth G.L., Henderer J., Liu C. et al. The disc damage likelihood scale: reproducibility of a new method of estimating the amount of optic nerve damage caused by glaucoma. Trans Am Ophthalmol Soc. 2002; 100: 181-185.
  160. Ernest P., Viechtbauer W., Schouten J.S. et al. The influence of the assessment method on the incidence of visual field progression in glaucoma: a network meta-analysis. Acta Ophthalmol. 2012; 90(1): 10-19.
  161. Yanagisawa M., Murata H., Matsuura M. et al. Investigating the structure-function relationship using Goldmann V standard automated perimetry where glaucomatous damage is advanced. Ophthalmic Physiol Opt. 2019; 39: 441-450.
  162. Mowatt G., Burr J.M., Cook J.A. et al. Screening tests for detecting open-angle glaucoma: systematic review and meta-analysis. Invest Ophthalmol Vis Sci. 2008; 49(12): 5373-5385.
  163. Doughty M.J., Zaman M.L. Human corneal thickness and its impact on intraocular pressure measures: a review and meta-analysis approach. Surv Ophthalmol. 2000; 44(5): 367-408.
  164. Ehlers N., Bramsen T., Sperling S. Applanation tonometry and central corneal thickness. Acta Ophthalmol (Copenh). 1975; 53(1): 34-43.
  165. Belovay G.W., Goldberg I. The thick and thin of the central corneal thickness in glaucoma. Eye (Lond). 2018; 32(5): 915-923.
  166. Аветисов С.Э., Бубнова И.А., Антонов А.А. Биомеханические свойства роговицы: клиническое значение, методы исследования, возможности систематизации подходов к изучению. Вестник офтальмологии. 2010; 126(6): 3- 7.
  167. Herman D.C. Increased corneal thickness in patients with ocular hypertension. Arch. Ophthalmol. 2001; 119(3): 334-336.
  168. Kansal V., Armstrong J.J., Pintwala R., Hutnik C. Optical coherence tomography for glaucoma diagnosis: An evidence based meta-analysis. PLoS One. 2018; 13(1): e0190621.
  169. Нероев В.В., Шамшинова А.М. Электрофизиологические методы исследования / В кн. Офтальмология. Национальное руководство под ред. С.Э. Аветисова, Е.А. Егорова, Л.К. Мошетовой, В.В. Нероева, Х.П. Тахчиди. М.: ГЭОТАР-Медиа, 2008: 159-175.
  170. Волков В.В. Глаукома открытоугольная. М.: Медицинское информационное агентство, 2008: 352.
  171. Волков В.В. Глаукома при псевдонормальном давлении. М.: Медицина, 2001: 352.
  172. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998; 126(4): 498-505.
  173. Lichter P.R., Musch D.C., Gillespie B.W. et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001; 108(11): 1943-1953.
  174. Heijl A., Leske M.C., Bengtsson B. et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002. 120(10): 1268-1279.
  175. Авдеев Р.В., Александров А.С., Бакунина Н.А. и др. Сопоставление режимов лечения больных с первичной открытоугольной глаукомой с характеристиками прогрессирования заболевания. Часть 1. Состояние показателей офтальмотонуса. Национальный журнал глаукома. 2018; 17(1): 14-28.
  176. Musch D.C., Gillespie B.W., Niziol L.M. et al. CIGTS Study Group. Intraocular pressure control and long-term visual field loss in the Collaborative Initial Glaucoma Treatment Study. Ophthalmology. 2011; 118(9): 1766-1773.
  177. Chauhan B.C., Garway-Heath D.F., Goni F.J. et al. Practical recommendations for measuring rates of visual field change in glaucoma. Br J Ophthalmol 2008; 92: 569- 573.
  178. Budenz D.L., Anderson D.R., Feuer W.J. et al. Detection and prognostic significance of optic disc hemorrhages during the Ocular Hypertension Treatment Study. Ophthalmology. 2006;113(12):2137-2143
  179. Herman D.C., Gordon M.O., Beiser J.A. et al. Topical ocular hypotensive medication and lens opacification: evidence from the ocular hypertension treatment study. Am J Ophthalmol. 2006; 142(5): 800-810;
  180. Bhorade A.M., Wilson B.S., Gordon M.O. et al. The utility of the monocular trial: data from the ocular hypertension treatment study. Ophthalmology. 2010; 117(11): 2047-2054
  181. Barnett E.M., Fantin A., Wilson B.S. et al. The incidence of retinal vein occlusion in the ocular hypertension treatment study. Ophthalmology. 2010; 117(3): 484-488.
  182. Miglior S., Pfeiffer N., Torri V. et al. Predictive factors for open-angle glaucoma among patients with ocular hypertension in the European Glaucoma Prevention Study. Ophthalmology. 2007; 114(1): 3-9.
  183. Medical Treatment of Glaucoma. WGA Consensus Series - 7. / Eds. Weinreb R., Makoto A., Susanna R., Goldberg I., Migdal C., Liebmann J. Kugler Publications, 2010: 309.
  184. Kobelt G. Comparative data for all countries. In: Primary open-angle glaucoma. Differences in international treatment patterns and costs. / Eds. Jönsson B., Krieglstein G. Oxford, England: ISIS Medical Media, 1998: 116-126.
  185. Куроедов А.В., Брежнев А.Ю., Ловпаче Дж.Н. и др. Целесообразность применения дифференцированных («ступенчатых») стартовых подходов к лечению больных с разными стадиями глаукомы. Национальный журнал глаукома. 2018; 3: 77-85.
  186. Куроедов А.В., Кондракова И.В., Городничий В.В., Гапонько О.В Клинические возможности предотвращения толератности при использовании комбинированной терапии у больных с первичной открытоугольной глаукомой. Военно-медицинский журнал. 2019; 5: 50-58.
  187. Li T., Lindsley K., Rouse B. et al. Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis. Ophthalmology. 2016; 123(1): 129-140.
  188. Li F., Huang W., Zhang X. Efficacy and safety of different regimens for primary open- angle glaucoma or ocular hypertension: a systematic review and network meta-analysis Acta Ophthalmol. 2018; 96(3): e277-e284.
  189. Fung A.T., Reid S.E., Jones M.P. et al. Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma. Br J Ophthalmol. 2007; 91(1): 62-68.
  190. Tang W., Zhang F., Liu K. et al. Efficacy and safety of prostaglandin analogues in primary open-angle glaucoma or ocular hypertension patients. A meta-analysis. Medicine. 2019; 98(30): e16597.
  191. Konstas A.G., Katsanos A.G., Quaranta L. et al. Twenty-four hour efficacy of glaucoma medications. Prog Brain Res. 2015; 221: 297-318.
  192. Van der Valk R., Webers S.A.B., Schouten J.S.A.G. et al. Intraocular pressure- lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology. 2005; 112(7): 1177-1185.
  193. Erb C. Glaucoma and Dry Eye. Bremen: UNI-MED Verlag AG, 2012: 102.
  194. Erb C., Lanzl I., Seidova S.F., Kimmich F. Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension. Adv Ther. 2011; 28(7): 575-585.
  195. Uusitalo H., Egorov E., Kaarniranta K. et al. Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials. Clin Ophthalmol. 2016; 10: 445-454.
  196. Zhang X., Vadoothker S., Munir W.M., Saeedi O. Ocular Surface Disease and Glaucoma Medications: A Clinical Approach. Eye Contact Lens. 2019; 45(1): 11-18.
  197. Бржеский В.В. Глаукома и синдром «сухого» глаза. М.: ООО «Компания БОРГЕС», 2018: 228.
  198. Lin L., Zhao Y.J., Chew P.T. et al. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension. Ann Pharmacother. 2014; 48(12): 1585-1593.
  199. Liu A.W., Gan L.Y., Yao X., Zhou J. Long-term assessment of prostaglandin analogs and timolol fixed combinations vs prostaglandin analogs monotherapy. Int J Ophthalmol. 2016; 9(5): 750-756.
  200. Cheng J.W., Li Y., Wei R.L. Systematic review of intraocular pressure-lowering effects of adjunctive medications added to latanoprost. Ophthalmic Res. 2009; 42(2): 99-105.
  201. Liu Y., Zhao J., Zhong X. et al. Efficacy and Safety of Brinzolamide as Add-On to Prostaglandin Analogues or β-Blocker for Glaucoma and Ocular Hypertension: A Systematic Review and Meta-Analysis. Front. Pharmacol. 2019; 10: 679-689.
  202. Olthoff C.M., Schouten J.S., van de Borne B.W., Webers C.A. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology. 2005; 112(6): 953-961.
  203. Kymes S.M., Plotzke M.R., Kass M.A. et al. Effect of patient’s life expectancy on the cost-effectiveness of treatment for ocular hypertension. Arch. Ophthalmol. 2010; 128(5): 613-618.
  204. Ho J.D., Hu C.C., Lin H.C. Antiglaucoma medications during pregnancy and the risk of low birth weight: a population-based study. Br. J. Ophthalmol. 2009;93(10):1283- 1286.
  205. Чернякова Т.В., Брежнев А.Ю., Газизова И.Р. и др. Особенности течения и лечения глаукомы в период беременности. Клиническая медицина. 2020; 98(3): 178-184.
  206. Gazzard G., Konstantakopoulou E., Garway-Heath D. et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet. 2019; 393(10180): 1505-1516.
  207. Kennedy J.B., SooHoo J.R., Kahook M.Y., Seibold L.K. Selective Laser Trabeculoplasty: An Update. Asia Pac J Ophthalmol (Phila). 2016; 5(1): 63-69.
  208. Garg A., Gazzard G. Selective laser trabeculoplasty: past, present, and future. Eye (Lond). 2018; 32(5): 863-876.
  209. Zhang L., Weizer J.S., Musch D.C. Perioperative medications for preventing temporarily increased intraocular pressure after laser trabeculoplasty. Cochrane Database Syst Rev. 2017. 23;2:CD010746.
  210. Wong M.O., Lee J.W., Choy B.N. et al. Systematic review and meta-analysis on the efficacy of selective laser trabeculoplasty in open-angle glaucoma. Surv Ophthalmol. 2015; 60(1): 36-50.
  211. McAlinden C. Selective laser trabeculoplasty (SLT) vs other treatment modalities for glaucoma: systematic review. Eye (Lond). 2014; 28(3): 249-258.
  212. Michelessi M., Lindsley K. Peripheral iridotomy for pigmentary glaucoma. Cochrane Database Syst Rev. 2016; 2: D005655.
  213. Соколовская Т.В., Дога А.В., Магарамов Д.А., Кочеткова Ю.А. YAG-лазерная активация трабекулы в лечении больных первичной открытоугольной глаукомой. Офтальмохирургия. 2014; 1: 47-52.
  214. Ramdas W.D. The relation between dietary intake and glaucoma: a systematic review. Acta Ophthalmol. 2018; 96(6): 550-556.
  215. Loskutova E., O’Brien C., Loskutov I., LoughmanJ. Nutritional supplementation in the treatment of glaucoma: A systematic review. Surv Ophthalmol. 2019; 64(2): 195- 216.
  216. Sena D.F., Lindsley K. Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst Rev. 2017; 1: CD006539.
  217. Chang E.E., Goldberg J.L. Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement. Ophthalmology 2012; 119(5): 979-986&
  218. Weinreb R.N., Goldberg I. Recent advances in glaucoma neuroprotection. Int Glaucoma Rev. CME Supplement. 2007; 9-3: 30-31.
  219. Лоскутов И.А., Саверская Е.Н., Лоскутова Е.И. Ретинопротекция как терапевтическая стратегия глаукомы: обзор исторических и современных мировых тенденций. Национальный журнал глаукома. 2016; 16(4): 86-97.
  220. Morrone L.A., Rombolà L., Adornetto A. et al. Rational Basis for Nutraceuticals in the Treatment of Glaucoma. Curr Neuropharmacology, 2018; 16: 1004-1017.
  221. Francis B.A., Varma R., Vigen C. et al. Los Angeles Latino Eye Study Group. Population and high-risk group screening for glaucoma: the Los Angeles Latino Eye Study. Invest Ophthalmol Vis Sci. 2011; 52(9): 6257-64.
  222. Glaucoma: Diagnosis and Management / Ed. J. Sparrow. London: NICE, 2017: 324.
  223. Melancia D., AbegãoPinto L., Marques-Neves C. Cataract Surgery and Intraocular Pressure. Ophthalmic Res 2015; 53: 141-148.
  224. Mansberger S.L., Gordon M.O., Jampel H.D. et al. Reduction in intraocular pressure after cataract extraction: the Ocular Hypertension Treatment Study. Ophthalmology. 2012; 119: 1826-1831.
  225. Ahmad M., Chocron I., Shrivastava A. Considerations for refractive surgery in the glaucoma patient. Curr Opin Ophthalmol. 2017; 28(4): 310-315.
  226. Kozobolis V., Konstantinidis A., Sideroudi H., Labiris G. The Effect of Corneal Refractive Surgery on Glaucoma. J Ophthalmol (Hindawi). 2017; 2017: 8914623.
  227. Shen L., Melles R.B., Metlapally R. et al. The Association of Refractive Error with Glaucoma in a Multiethnic Population. Ophthalmology. 2016; 123(1): 92-101.
  228. Park H.Y., Choi S.I., Choi J.A., Park C.K. Disc torsion and vertical disc tilt are related to subfoveal scleral thickness in open-angle glaucoma patients with myopia. Invest Ophthalmol Vis Sci. 2015; 56(8): 4927-4935.
  229. Shin H.Y., Park H.Y., Park C.K. The effect of myopic optic disc tilt on measurement of spectral-domain optical coherence tomography parameters. Br J Ophthalmol. 2015; 99(1): 69-74.
  230. Akashi A., Kanamori A., Ueda K. et al. The ability of SD-OCT to differentiate early glaucoma with high myopia from highly myopic controls and non-highly myopic controls. Invest Ophthalmol Vis Sci. 2015; 56(11): 6573-6580.
  231. Khawaja A.P., Chan M.P., Broadway D.C. et al. Systemic medication and intraocular pressure in a British population: the EPIC-Norfolk Eye Study. Ophthalmology. 2014; 121(8): 1501-1507.
  232. Masnoon N., Shakib S., Kalisch-Ellett L., Caughey G.E. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017; 17(1): 230-239.
  233. Wu A., Khawaja A.P., Pasquale L.R., Stein J.D. A review of systemic medications that may modulate the risk of glaucoma. Eye. 2020; 34: 12-28.
  234. Roughead E.E., Kalisch L.M., Pratt N.L., Killer G. et al. Managing glaucoma in those with co-morbidity: not as easy as it seems. Ophthalmic Epidemiol. 2012; 19(2): 74-82.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*